CROI 2024 Program Guide

Interactive Symposia

32 | 4:00 PM | Novel Markers of Hepatitis B: Clinical Utility for New Treatment Strategies Fabien Zoulim , L’Université Claude Bernard Lyon 1, Lyon, France

33 | 4:25 PM | Advances in HBV Immunotherapy: The Beginning of the End? Adam Gehring , University of Toronto, Toronto, Canada 34 | 4:50 PM | How New WHO Guidance Might Transform Hepatitis B in Sub-Saharan Africa Olufunmilayo Lesi , World Health Organization, Geneva, Switzerland

5:10 PM | International Perspectives on Hepatitis B: Panel Discussion

Anna S. Lok , University of Michigan, Ann Arbor, MI, USA

Beatriz Grinsztejn , Oswaldo Cruz Foundation - Fiocruz, Rio de Janeiro, Brazil Olufunmilayo Lesi , World Health Organization, Geneva, Switzerland Lived Experience: Wes Spurr , Denver, CO, USA

Fabien Zoulim , L’Université Claude Bernard Lyon 1, Lyon, France Chien-Ching Hung , National Taiwan University Hospital, Taipei, Taiwan

Tuesday

Interactive Symposium-06 | Roundtable on DoxyPEP: Ready or Not… 4:00 PM - 5:30 PM • Mile High Ballroom 1-2-3 CME Objectives: At the completion of the session, participants will be able to: • Describe findings about efficacy, adherence, and acceptability of doxyPEP in trials among men who have sex with men, transgender women, and cisgender women • Explain the concerns and available data about antimicrobial resistance in STIs and bystander bacteria • Describe doxyPEP guidelines, early implementation approaches, and uptake Target Audience: This session is directed to clinicians, program managers, and community members interested in doxycycline postexposure prophylaxis (doxyPEP) for sexually transmitted infection (STI) prevention Level of Knowledge: It is assumed that the participants are familiar with the concept of doxycycline for STI prevention

CROI 2024 50

New Investigator Scholarship

LB

NIS

Late-Breaking